EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Plasma Proteome‐Wide Mendelian Randomization Analysis Reveals Biomarkers and Therapeutic Targets for Different Stages of COVID‐19

Suhas Krishnamoorthy, Ruby Lai Chong Hoo, Ching Lung Cheung iD

Transboundary and Emerging Diseases · 2024-01 · 2024 (1)

DOI: 10.1155/2024/5566180 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transboundary and Emerging Diseases, online erschienen am 05.02.2024. Verfasst von Suhas Krishnamoorthy und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China. Hauptthemen laut MEDLINE: COVID-19, Proteome, Blood Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JULAC 2023.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The COVID‐19 pandemic caused by the SARS‐CoV‐2 virus has resulted in a global health crisis with significant morbidity and mortality. While effective vaccinations have been developed, drug treatments for the disease are still required, particularly for different stages of the disease and to combat evolving variants. Identifying reliable biomarkers and potential therapeutic targets for the different stages of COVID‐19 is crucial.

Methods

Mendelian randomization using the largest publicly available datasets was conducted to identify potential causal plasma proteins for severe COVID‐19, hospitalized COVID‐19, and SARS‐CoV‐2 infection. Independent, and strongly associated cis‐ or pan‐pQTLs were used as instrumental variables for each protein. The FDR q ‐value was used to correct for multiple testing followed by sensitivity analyses, reverse MR and genetic colocalization to ensure the robustness of the results.

Results

We identified proteins with strong evidence of causal association with different stages of COVID‐19. Some of these proteins were identified previously, such as BGAT and BCAT2, but we also identified the novel proteins, such as KLC1, MRVI1, CACO2, and PCNP.

Conclusion

These proteins provide valuable insights into the underlying mechanisms of COVID‐19. The identification of these proteins offers new opportunities for developing potential therapeutic targets or biomarkers for the treatment and prevention of COVID‐19.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19ProteomeBlood ProteinsHumansMendelian Randomization AnalysisBiomarkersSARS-CoV-2

Substanzen

BiomarkersProteomeBlood Proteins

Autor:innen und Institutionen

  • Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China.

ORCID-Profile: Ching Lung Cheung

Förderung

  • JULAC 2023

Zitieren

APA

Krishnamoorthy, S., Hoo, R. L. C., & Cheung, C. L. (2024). Plasma Proteome‐Wide Mendelian Randomization Analysis Reveals Biomarkers and Therapeutic Targets for Different Stages of COVID‐19. Transboundary and Emerging Diseases, 2024(1). https://doi.org/10.1155/2024/5566180

Vancouver

Krishnamoorthy S, Hoo RLC, Cheung CL. Plasma Proteome‐Wide Mendelian Randomization Analysis Reveals Biomarkers and Therapeutic Targets for Different Stages of COVID‐19. Transboundary and Emerging Diseases. 2024;2024(1). doi:10.1155/2024/5566180

BibTeX
@article{Krishnamoorthy2024,
  author = {Krishnamoorthy, Suhas and Hoo, Ruby Lai Chong and Cheung, Ching Lung},
  title = {Plasma Proteome‐Wide Mendelian Randomization Analysis Reveals Biomarkers and Therapeutic Targets for Different Stages of COVID‐19},
  journal = {Transboundary and Emerging Diseases},
  year = {2024},
  volume = {2024},
  number = {1},
  doi = {10.1155/2024/5566180}
}
Kostenlos starten →